Objectives: This study evaluated the efficacy and safety of an angle-supported phakic intraocular lens (PIOL) for the treatment of moderate to high myopia. Methods : This is a case series of 13 eyes of 8 patients with moderate to high myopia that underwent implantation of an acrylic, angle-supported PIOL. The main outcome measures were manifest refraction, uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), endothelial-cell count (ECC), intraocular pressure (IOP), and adverse events. Results: The mean spherical equivalent (SE) improved from –11.79 ± 4.12 diopters (D) preoperatively to –0.08 ± 0.58 D postoperatively (p = 0.000), UCVA from 0.016 ± 0.015 to 0.79 ± 0.29 postoperatively (p = 0.000), and BCVA from 0.76 ± 0.33 to 0.86 ± 0.27 (p = 0.017). The ECC slightly decreased from 3033.57 ± 367.71 cells/mm2 preoperatively to 2947 ± 279.86 cells/mm2 (2.8% loss) postoperatively (p = 0.400). The mean preoperative IOP was 16.36 ± 3.53 mm Hg while the mean three-month postoperative IOP was 15.72 ± 4.15 mm Hg (p = 0.659). Two (15%) eyes experienced transient postoperative IOP rise on the day of the surgery, which resolved by postoperative day 1 using topical timolol maleate. The mean follow-up was 2.54 ± 1.39 months (range, 1 to 5 months). Conclusion Acrylic angle-supported phakic intraocular lens (PIOL) implantation is an effective and safe method of correcting moderate to high myopia.
Refractive Surgical Procedures